Migraine - Pipeline Review, H1 2020

May 2020 | 313 pages | ID: M6964163929EN
Global Markets Direct

Abstracts

Migraine - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Migraine – Pipeline Review, H1 2020, provides an overview of the Migraine (Central Nervous System) pipeline landscape.

Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and extreme sensitivity to light and sound. Symptoms include problems speaking, tingling in face, arms, and shoulders, pain behind one of the eyes and pain that gets worse with routine physical activity.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Migraine – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Migraine (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Migraine (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Migraine and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 11, 15, 11, 1, 31, 4 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 3 molecules, respectively.

Migraine (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Migraine (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Migraine (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Migraine (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Migraine (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Migraine (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Migraine (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Migraine (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Migraine - Overview
Migraine - Therapeutics Development
Migraine - Therapeutics Assessment
Migraine - Companies Involved in Therapeutics Development
Migraine - Drug Profiles
Migraine - Dormant Projects
Migraine - Discontinued Products
Migraine - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Migraine, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Migraine - Pipeline by 4P Therapeutics LLC, H1 2020
Migraine - Pipeline by Achelios Therapeutics Inc, H1 2020
Migraine - Pipeline by Acorda Therapeutics Inc, H1 2020
Migraine - Pipeline by AgoneX Biopharmaceuticals Inc, H1 2020
Migraine - Pipeline by Allergan Plc, H1 2020
Migraine - Pipeline by Allodynic Therapeutics LLC, H1 2020
Migraine - Pipeline by Amgen Inc, H1 2020
Migraine - Pipeline by AOBiome LLC, H1 2020
Migraine - Pipeline by Aptarion biotech AG, H1 2020
Migraine - Dormant Projects, H1 2020
Migraine - Dormant Projects, H1 2020 (Contd..1), H1 2020
Migraine - Dormant Projects, H1 2020 (Contd..2), H1 2020
Migraine - Dormant Projects, H1 2020 (Contd..3), H1 2020
Migraine - Dormant Projects, H1 2020 (Contd..4), H1 2020
Migraine - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Migraine, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

4P Therapeutics LLC
Achelios Therapeutics Inc
Acorda Therapeutics Inc
AgoneX Biopharmaceuticals Inc
Allergan Plc
Allodynic Therapeutics LLC
Amgen Inc
AOBiome LLC
Aptarion biotech AG
Asarina Pharma AB
Astrocyte Pharmaceuticals Inc
Avanir Pharmaceuticals Inc
Axsome Therapeutics Inc
Better Life Pharmaceuticals Inc
Biohaven Pharmaceutical Holding Company Ltd
Blackthorn Therapeutics Inc
Cerecin Inc
CerSci Therapeutics Inc
Charleston Laboratories Inc
Citragen Pharmaceuticals Inc
Corium, Inc.
Crossject SA
Curatis AG
CURx Pharmaceuticals Inc
DelNova Inc
Eli Lilly and Co
Epalex Corp
Exxel Pharma Inc
H. Lundbeck AS
Impel NeuroPharma Inc
InKemia IUCT Group SA
InStar Technologies AS
IntelGenx Corp
Invisio Ltd
Ionis Pharmaceuticals Inc
Klaria Pharma Holding AB
Lateral Pharma Pty Ltd
Living Cell Technologies Ltd
MannKind Corp
Medytox Inc
Merck & Co Inc
NAL Pharmaceuticals Ltd
NeurAxon Pharma Inc
NutriBand Inc
OWP Pharmaceuticals Inc
Panaxia Pharmaceutical Industries Ltd
Pharmaleads SA
Pharmnovo AB
Pherin Pharmaceuticals Inc
Promius Pharma LLC
Qingdao Chia Tai Haier Pharmaceutical Co Ltd
RAFT Pharmaceuticals
Revance Therapeutics Inc
Satsuma Pharmaceuticals Inc
Seurat Therapeutics Inc
Shanghai Junshi Bioscience Co Ltd
Shin Nippon Biomedical Laboratories Ltd
Sorrento Therapeutics Inc
Sosei Heptares
Suda Pharmaceuticals Ltd
Teva Pharmaceutical Industries Ltd
Trevena Inc
Trigemina Inc
TrioxBio Inc
United Neuroscience Ltd
Xenon Pharmaceuticals Inc
Xoc Pharmaceuticals Inc
Zosano Pharma Corp